We are monitoring the impact of COVID-19 on North America Cancer Immunotherapy Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1337
Share on
Share on

North America Cancer Immunotherapy Market Research Report – Segmented By Application, Product Type, Mode Of Administration, End Users, Country (United States, Canada and Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, Forecast | 2020 to 2025

Pulished: February, 2020
ID: 1337
Pages: 132

North America Cancer Immunotherapy Market Size (2020 to 2025)

As per our report, the size of the Cancer Immunotherapy Market in North America was worth USD 25.22 Billion in 2020 and estimated to reach USD 44.84 Billion by the end of 2025 with a growing potential of 12.20%.

The patient population is growing as they suffer from various types of cancer such as ovarian cancer, lung cancer, breast cancer and others, which are the factors that drive the North America cancer immunotherapy market during the review period. The rise in incidence and prevalence of cancer, advance treatment therapies, treatment for a wide range of cancer are also the key factors that drive the growth of the North American market of cancer immunotherapy. 

This market is further driven by the smoking, consumption of alcohol, changing lifestyle, and other factors, which results in the increased possibility of occurrence of cancer.

Treatment-free-survival (TFS) provides a significant opportunity to the patients and their family members to resume their routine activities like they can travel and can also do their daily activities which are free from ongoing cancer treatment. Another opportunity is, patients who are in their last stage of cancer, face the possibility of dying. Here the opportunity is to pursue a risky action for success in their life, i.e., taking a novel therapy, which offers the patient a potentiality for long term disease in a small percentage than a long or high proportion.

In cancer immunotherapy, economic modelling is challenging because the mechanism of the disease varies by location of the patient body, tumour type. The important restraint in the regional market is the high treatment cost. Constraints that control the growth of cancer immunotherapy across the North American market are having a smaller number of skilled healthcare experts and also the lack of awareness among the population.

The previous treatment may impact the effects of the therapy, which the patient has undergone in his past. In immuno-oncology therapies, the price and reimbursement of these remain a crucial challenge for the decision-makers during the market launch. Some of the unique challenges in the selection of clinical outcomes and also the development of uniform methods and metrics to capture the correct results is highlighted. There are some challenges to incorporate PRO measures to the existing value frameworks.

This research report has been segmented & sub-segmented into the following categories:

  • By Type of Therapies: Immune System Modulators, Immune Checkpoint Inhibitors & Monoclonal Antibodies
  • By Area of Therapy: Blood Cancer, Prostate Cancer, Melanoma, Breast Cancer, Lung Cancer, Colorectal Cancer & Other Minor Areas
  • By Country: the United States, Canada and Rest of North America

Regional Analysis:

North America held the largest share in the global cancer immunotherapy market, which is attributed to the major contribution from the United States. The increasing cancer patients, presence of sophisticated medical infrastructure, continuous research and development activities and the availability of product manufactures are the main aspects supporting the United States cancer immunotherapy market, which further boosts the North American business.

Some of the major companies dominating in North America cancer immunotherapy Market are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co. and Celgene Corp and Immunomedics.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Application                 

                                5.1.1 Introduction           

                                5.1.2 Breast       

                                5.1.3 Lung          

                                5.1.4 Melanoma              

                                5.1.5 Colorectal

                                5.1.6 Head & Neck          

                                5.1.7 Prostate   

                                5.1.8 Others      

                                5.1.9 Y-o-Y Growth Analysis, By Application         

                                5.1.10 Market Attractiveness Analysis, By Application     

                                5.1.11 Market Share Analysis, By Application      

                5.2 Product Type                             

                                5.2.1 Introduction           

                                5.2.2 Monoclonal Antibodies     

                                5.2.3 Checkpoint inhibitors/immune modulators              

                                5.2.4 Therapeutic cancer vaccines            

                                5.2.5 Oncolytic virus immunotherapy     

                                5.2.6 Cytokines

                                5.2.7 Adoptive T cell transfer     

                                5.2.8 Adjuvant Immunotherapy

                                5.2.9 Interferons             

                                5.2.10 Interleukins         

                                5.2.11 BCG         

                                5.2.12 Others   

                                5.2.13 Y-o-Y Growth Analysis, By Product Type   

                                5.2.14 Market Attractiveness Analysis, By Product Type

                                5.2.15 Market Share Analysis, By Product Type  

                5.3 Mode of Administration                        

                                5.3.1 Introduction           

                                5.3.2 Intravenous           

                                5.3.3 Oral            

                                5.3.4 Topical      

                                5.3.5 Intra Vesical           

                                5.3.6 Y-o-Y Growth Analysis, By Mode of Administration

                                5.3.7 Market Attractiveness Analysis, By Mode of Administration              

                                5.3.8 Market Share Analysis, By Mode of Administration

                5.3 End users                    

                                5.3.1 Introduction           

                                5.3.2 Hospitals  

                                5.3.3 Clinics        

                                5.3.4 Y-o-Y Growth Analysis, By End users            

                                5.3.5 Market Attractiveness Analysis, By End users           

                                5.3.6 Market Share Analysis, By End users            

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Application

                                                6.1.3.3 By Product Type

                                                6.1.3.4 By Mode of Administration

                                                6.1.3.5 By End users

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Application

                                                6.1.4.3 By Product Type

                                                6.1.4.4 By Mode of Administration

                                                6.1.4.5 By End users

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Application

                                                6.1.5.3 By Product Type

                                                6.1.5.4 By Mode of Administration

                                                6.1.5.6 By End users

                6.2 United States                            

                6.3 Canada                         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 F. Hoffmann-La Roche Ltd                    

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Amgen                         

                8.3 Viralytics                      

                8.4 Novartis Pharmaceuticals Corporation                            

                8.5 Pfizer                            

                8.6 GlaxoSmithKline Pharmaceuticals Limited                     

                8.7 AstraZeneca plc                        

                8.8 Medivation                

                8.9 Advaxis                        

                8.10 Bristol-Myers Squibb                           

                8.11 Merck & Co. and Celgene Corp                        

                8.12 Immunomedics                      

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. North America Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  2. North America Breast Market By Region, From 2020 to 2025 (USD Billion)
  3. North America Lung Market By Region, From 2020 to 2025 (USD Billion)
  4. North America Melanoma Market By Region, From 2020 to 2025 (USD Billion)
  5. North America Colorectal Market By Region, From 2020 to 2025 (USD Billion)
  6. North America Head & Neck Market By Region, From 2020 to 2025 (USD Billion)
  7. North America Prostate Market By Region, From 2020 to 2025 (USD Billion)
  8. North America Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  9. North America Monoclonal Antibodies Market By Region, From 2020 to 2025 (USD Billion)
  10. North America Checkpoint inhibitors/immune modulators Market By Region, From 2020 to 2025 (USD Billion)
  11. North America Therapeutic cancer vaccines Market By Region, From 2020 to 2025 (USD Billion)
  12. North America Oncolytic virus immunotherapy Market By Region, From 2020 to 2025 (USD Billion)
  13. North America Cytokines Market By Region, From 2020 to 2025 (USD Billion)
  14. North America Adoptive T cell Transfer Market By Region, From 2020 to 2025 (USD Billion)
  15. North America Adjuvant immunotherapy Market By Region, From 2020 to 2025 (USD Billion)
  16. North America Interferons Market By Region, From 2020 to 2025 (USD Billion)
  17. North America Interleukins Market By Region, From 2020 to 2025 (USD Billion)
  18. North America BCG Market By Region, From 2020 to 2025 (USD Billion)
  19. North America Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  20. North America Intravenous Market By Region, From 2020 to 2025 (USD Billion)
  21. North America Oral Market By Region, From 2020 to 2025 (USD Billion)
  22. North America Topical Market By Region, From 2020 to 2025 (USD Billion)
  23. North America Intravesical Market By Region, From 2020 to 2025 (USD Billion)
  24. North America Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)
  25. North America hospitals Market By Region, From 2020 to 2025 (USD Billion)
  26. North America Clinics Market By Region, From 2020 to 2025 (USD Billion)
  27. United States Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  28. United States Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  29. United States Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  30. United States Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)
  31. Canada Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  32. Canada Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  33. Canada Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  34. Canada Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample